Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC.

JTO Clin Res Rep · 2024 · PMC11126925 · PMID 38799131

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In addition, there was a nonsignificant trend for fewer metastatic lesions correlating with improved outcomes ( Supplementary Table 2 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.